Company news

Aldeyra Therapeutics, Inc. news in 2025

Aldeyra Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease

December 15, 2025

Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast

November 13, 2025

Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

November 11, 2025

Aldeyra Therapeutics to Host Research & Development Update Webcast Event Scheduled for Thursday, November 13 at 8: 00 a.m. ET

November 6, 2025

Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules

October 28, 2025

Alkermes Appoints Joshua Reed as Chief Financial Officer

September 12, 2025

Aldeyra Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

September 3, 2025

Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal Lymphoma

August 28, 2025

Aldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa

August 19, 2025

Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

August 6, 2025

Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa

July 24, 2025

Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease

July 17, 2025

Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma

June 26, 2025

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

June 17, 2025

Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference

May 29, 2025

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission

May 5, 2025

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap

May 5, 2025

Aldeyra Therapeutics Appoints Chip Clark to Board of Directors

April 17, 2025

Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease

April 3, 2025

Aldeyra Therapeutics to Participate in the 2025 Leerink Partners Global Healthcare Conference

March 10, 2025

Aldeyra Therapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference

February 3, 2025

Calls in 2025

Decks in 2025